Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06592378

Opioid Management for Discharged Emergency Department Patients

The goal of this study is to analyze the use of the Addinex system for opioid dispensing after ambulatory care to determine whether it will reduce opioid consumption, increase pill disposal, show variables that may predict opioid consumption, and determine whether this intervention is acceptable to patients.

Recruiting

Interested in participating?

Request Info

Key information

Age range

6 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Rhode Island Hospital/Lifespan

Providence, Rhode Island, 02903, United States

Location status: Recruiting

Location contact

Geoffrey Capraro, MD, MPH

CONTACT

[email protected]

508-410-2215

Geoffrey Capraro, MD, MPH

PRINCIPAL_INVESTIGATOR

Tanushree Girish, MPH

CONTACT

[email protected]

401-606-9814

About this study

Prescription opioids remain a popular drug class with 143 million (M) opioid prescriptions written in 2020. In that same year, 8.7 million people (2.6% of the US population) misused prescription pain relievers, and overdose deaths from opioids continue to rise to 83,695 in 2022. Across six studies, 67% to 92% of patients prescribed opioids reported unused pills. In 2017, patients were prescribed 3.3 billion excess pills, yet no more than 9% of patients properly disposed of their unused opioids. Despite attempts to reduce overprescribing, increase disposal, and decrease diversion, these issues still contribute to increasing misuse, addiction, and overdose deaths.

Addinex Technologies has developed a novel system to reduce the use of opioids through controlling, monitoring, and disposing of excess opioids. The unique "closed-loop" system starts with clinicians prescribing opioids with the Addinex system. Addinex's partner pharmacy then fills the patented dispenser and delivers it to the patient. The patient uses the Addinex app to access each individual dose code and to obtain education and feedback. Finally, the patient returns the dispenser with any excess pills in a DEA-approved mailer to Addinex's partner disposal company. In a study with Columbia University Medical Center using the Addinex system with 30 post-surgical cancer patients, results showed 70% fewer pills used than prescribed, 60% fewer refills for the same surgeries, and an 84% excess pill disposal rate.

Addinex is now partnering with Brown Emergency Medicine and Rhode Island Hospital ("Brown") to perform a feasibility study using Addinex's system. We will conduct a clinical trial involving 100 patients with extremity fractures treated by the emergency department. Half the patients (25 adults and 25 minors) will utilize the Addinex system, while the other half will have their opioids dispensed in a standard pill bottle as the control group. Addinex's system promotes the return of medication using a pre-paid disposal mailer once patients have completed their course of treatment. The clinical study's main goals involve evaluating the system's effectiveness with patients obtaining same day treatment. This evaluation will encompass an analysis of medication consumption, disposal rates, pain levels, the impact of monitoring policies, and ensuring that the established commercial protocols function seamlessly. Ultimately, the project aims to demonstrate that the Addinex system can successfully operate within the broader hospital environment (same day and scheduled procedures), controlling and monitoring opioid usage, promoting patient well-being, and lowering costs.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Ages six years and older
  • Ability to swallow pills
  • Isolated bone fracture
  • Planned to receive opioids in the post-treatment period
  • Not taking opioids daily prior to the procedure
  • English or Spanish-speaking
  • Able to give informed consent or a parent that can give informed consent
  • Ownership of and comfort using apps on a smartphone with compatible operating system
  • WIFI or cellular access
  • Patient not admitted to hospital

Exclusion criteria

  • Recent opioid use (last 30 days or 2 or more prescriptions in the past 3 months
  • Impaired decisional capacity
  • In police custody
  • Ward of the state

Treatment and study plan

Addinex

Device

Medication dispensing system to control and monitor opioid use

Standard Pill Bottle

Device

Access and use of opioids in a standard pill bottle.

Primary outcomes

  1. Median pill consumption

    Time frame: One month post treatment

    Patients are expected to consume at least 16% fewer pills/MMEs using the Addinex system as compared to the control group.

Secondary outcomes

  1. Median disposal of opioids

    Time frame: 12 months post treatment

    Patients are expected to dispose of at least 50% of excess opioid pills using the Addinex system vs. 20% in the control group.

Study contacts

Contact information is provided by the study sponsor or research team.

Geoffrey Capraro, MD, MPH

CONTACT

[email protected]

508-410-2215

Sponsors and collaborators

Lead sponsor

Addinex Technologies, Inc.

Industry

Collaborators

  • National Institute on Drug Abuse (NIDA)

Registry information

Official study title

Integration of an Opioid Dispensing, Monitoring, and Disposal Platform With a Hospital Pharmacy to Reduce Opioid Use by Discharged Emergency Department Patients

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Sep 19, 2024
Registry last updated
Dec 26, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.